ARCT ARCTURUS THERAPEUTICS HLDG I

Ownership history in UBS Group AG  ·  27 quarters on record

This page tracks every 13F SEC filing in which UBS Group AG reported a position in ARCTURUS THERAPEUTICS HLDG I (ARCT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 227,893 +67,407 +42.0% 0.00% $1.4M $6.13
2025 Q3 ADDED 160,486 +140,586 +706.5% 0.00% $3.0M $18.43
2025 Q3 REDUCED 19,900 -35,544 -64.1% 0.00% $367K $18.43
2025 Q2 REDUCED 55,444 -4,100 -6.9% 0.00% $721K $13.01
2025 Q1 ADDED 59,544 +6,473 +12.2% 0.00% $631K $10.59
2024 Q4 ADDED 53,071 +213 +0.4% 0.00% $901K $16.97
2024 Q3 REDUCED 52,858 -9,301 -15.0% 0.00% $1.2M $23.21
2024 Q2 REDUCED 62,159 -45,780 -42.4% 0.00% $1.5M $24.35
2024 Q1 ADDED 107,939 +35,231 +48.5% 0.00% $3.6M $33.77
2023 Q4 ADDED 72,708 +41,446 +132.6% 0.00% $2.3M $31.53
17 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    ARCT price (monthly, adj. close)
← Back to UBS Group AG Holdings